Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 19 years of age or older, have a reasonable level of daily functioning, and are expected to live for at least 12 weeks
- People who have been diagnosed with a type of blood cancer called B-cell lymphoma, confirmed by a tissue sample test
- People whose lymphoma has come back or stopped responding to treatment after at least two previous rounds of chemotherapy
- People who have at least one measurable area of disease that is 1.5 cm or larger
- People whose heart, organs, and lungs are functioning at an adequate level
- People whose heart pumping function (measured as LVEF) is at least 40%
- People who are able to undergo a procedure called leukapheresis, where white blood cells are collected from the blood
- People of childbearing potential who agree to use effective contraception for at least 6 months after receiving the study treatment
Who may not be able to join:
- People who still have unresolved side effects of a moderate or severe level from a previous treatment
- People who have had another cancer diagnosis within the past 2 years (some exceptions may apply — confirm with trial site)
- People who have had a significant heart condition within the past 6 months
- People whose lymphoma has spread to the brain or spinal cord
- People with an active infection of hepatitis B, hepatitis C, HIV, or syphilis
- People whose disease is considered to be rapidly getting worse, based on the treating doctor's assessment
- People who have had major surgery requiring general anaesthetic within the past 4 weeks
- People who have an active or uncontrolled infection
- People who have previously received certain treatments, including anti-CD19 therapies, adoptive T-cell therapy, gene therapy, or a donor stem cell transplant
- People who have recently used other experimental treatments or immune-suppressing medications within timeframes set by the trial (confirm with trial site)
- People who are pregnant or breastfeeding
- People who have a known allergy or sensitivity to any ingredient in the study treatment
- People who do not meet specific requirements related to the leukapheresis procedure, such as having received certain medications too recently (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 82+1029985238
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Phase1: Occurrence of Dose-Limiting Toxicities (DLTs); Phase1: Determination of Maximum Tolerated Dose (MTD); Phase1: Determination of Recommended Phase 2 Dose (RP2D); Phase 1: The number and incidence rate of treatment-emergent adverse events (TEAEs) as well as serious adverse events (SAEs) will be assessed; Phase1: Number of participants with abnormal physical examination findings; Phase1: Number of participants with abnormal vital signs; Phase1: Number of participants with abnormal ECG readings; Phase 1 : Number of participants with abnormal laboratory test results; Phase 1 : Presence of Re...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.